Clinical trialPhase 1Completed
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
A Phase I, Multicenter Dose-Escalation Study to Assess the Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of AZD5153 in Patients With Relapsed/Refractory Malignant Solid Tumors, Including Lymphomas
- Outcome
- Finished, no results posted
- Phase
- Phase 1
- Status
- Completed
- Study type
- Interventional
- Start
- 30 June 2017
- Ended
- 8 April 2021
- Enrollment
- 49 participants
- Sites
- 4
- Primary outcomes
- Incidence of dose-limiting toxicity (DLT).
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 6 May 2021
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with malignant solid tumors, including lymphomas.
Detailed description public domain (ClinicalTrials.gov)
The trial will be conducted in two parts, dose escalation and dose expansion. AZD5153 will be investigated as a monotherapy and in combination with olaparib. AZD5153 monotherapy (dose escalation): This part of the study will enroll patients with advanced solid malignancies, including lymphoma, and test safety and tolerability of AZD5153 administered as a monotherapy. The dose escalation will proceed by two-fold increments or through lower doses suggested by the CRM until an MTD as defined by dose-limiting toxicity is reached. Single daily (QD) and twice daily (BID) dosing schedules will be explored in the monotherapy cohort. Additional dose levels or dosing schedules may be evaluated and recommended by study Safety Review Committee (SRC) based on the emerging PK and safety data. When the AZD5153 monotherapy MTD is established, an expansion cohort consisting of up to 12 additional evaluable patients may be enrolled to confirm the safety and tolerability of the MTD. The dose expansion will be initiated and will enroll patients with histologically or cytologically confirmed platinum resistant or platinum-refractory high grade serous ovarian (HGSO) cancer. Mandatory tumor biopsies at screening for ovarian cancer patients will be required for patient enrollment in the MTD dose expansion cohort. Optional on-treatment biopsies will be requested from consenting patients in the ovarian expansion cohort. AZD5153 + olaparib combination: Dose escalation of AZD5153 in combination with olaparib will also be investigated while the AZD5153 monotherapy dose escalation is ongoing and prior to determination of a monotherapy MTD. The starting dose of AZD5153 in combination with olaparib will be a dose that has been shown to be safe and tolerated in monotherapy and has been chosen because clinical exposure achieved at this dose is equivalent to preclinical exposure causing tumour growth inhibition in animal models. If the starting dose in combination with olaparib is safe and tolerated, the dose of AZD5153 will be escalated, using the same method as for the monotherapy part of the study, keeping the olaparib dose fixed at 300 mg BID. Intermittent schedules as well as continuous BID or QD dosing of AZD5153 in combination with 300 mg BID olaparib might be tested until a safe and tolerated combination dose and schedule is determined. However, the total dose per cycle of AZD5153 used in combination with olaparib won't exceed the total dose per cycle that has been shown to be safe and tolerated as a monotherapy, and won't be higher than the dose declared to be the monotherapy MTD. If intermittent dosing is explored then the CRM will consider cumulative dosing rather than daily dosing. AZD5153 and olaparib will be administered in continuous cycles of 21 days. The combination dose escalation part will run in parallel with the AZD5153 monotherapy part (dose escalation and expansion) and will continue until a safe and tolerated combination dose of the two agents is declared. Mandatory paired tumor biopsies at screening and on-treatment will be required for patients enrolled into the combination dose escalation. Once a dose and schedule of AZD5153 in combination with olaparib is established, up to 12 additional evaluable patients might be enrolled to confirm the safety and tolerability of the dose and schedule of AZD5153 and olaparib in one or more of the indications where clinical activity is observed. Patients with platinum-resistant or platinum-refractory HGSO cancer, triple negative breast cancer, metastatic castration resistant prostate cancer, or pancreatic ductal adenocarcinoma will be eligible for the expansion cohort.
Intervention public domain (ClinicalTrials.gov)
Drug: AZD5153. AZD5153 is to be taken as oral capsules once or twice per day each day in 21 day cycles. Dosing will continue until disease progression or other study discontinuation criteria are met.
Intervention public domain (ClinicalTrials.gov)
Drug: Olaparib. Olaparib, 300 mg, will be taken BID as oral capsules.
Arm public domain (ClinicalTrials.gov)
AZD5153 Monotherapy (experimental): Patients will be enrolled in cohorts of up to 6 patients each in a dose escalating scheme to determine maximum tolerated dose (MTD). AZD5153 will be taken once per day (QD) or two times per day (BID) for 21 days as an oral capsule. Once the MTD is finalized, patients may be enrolled into an expansion cohort at the MTD.
Arm public domain (ClinicalTrials.gov)
AZD5153 + Olaparib Combination Therapy (experimental): Patients will be enrolled in cohorts of up to 6 patients each in a dose escalating scheme to determine MTD. AZD5153 will be taken as oral capsules BID in combination with 300 mg olaparib BID for 21 days.
Primary outcome public domain (ClinicalTrials.gov)
Incidence of dose-limiting toxicity (DLT).. DLTs will be determined from monitoring adverse events (AEs), and abnormal laboratory tests (clinical chemistry, hematology, and urinalysis), physical examinations, vital signs (blood pressure and pulse), and electrocardiogram (ECG). Time frame: From the first dose of study treatment up to last day of cycle 1 (21 days).
Secondary outcome public domain (ClinicalTrials.gov)
Peak plasma concentration (Cmax). Time frame: Samples for single dose PK will be collected at prespecified time points on Day 1, Cycle 1 pre-dose on Day 2. Multiple-dose PK will be assessed from samples taken on Days 15 and 16 of Cycle 1..
Secondary outcome public domain (ClinicalTrials.gov)
The urine concentration of AZD5153 and its co-former (if appropriate).. Time frame: Urine will be collected pre-dose (spot sample), and volumetrically from 0-6, 6-12, 12-24 hours on Day 1 and Day 15 of Cycle 1..
Secondary outcome public domain (ClinicalTrials.gov)
The effect of AZD 5153 on QTc interval.. Time frame: ECGs will be performed at prespecified time points on Days 1 and 2 and 15 and 16 of Cycle 1..
Secondary outcome public domain (ClinicalTrials.gov)
Antitumor activity of AZD5153 in patients by assessing the disease control rate (DCR).. Time frame: Up to 1 year.
Secondary outcome public domain (ClinicalTrials.gov)
Antitumor activity of AZD5153 in patients by assessing progression free survival (PFS).. Time frame: Up to 1 year.
Secondary outcome public domain (ClinicalTrials.gov)
Antitumor activity of AZD5153 in patients by assessing overall response rate (ORR).. Time frame: Up to 1 year.
Eligibility public domain (ClinicalTrials.gov)
Inclusion Criteria for all Patients: 1. Patient must be able to understand the nature of the study and provide a signed and dated, written informed consent prior to any study specific procedures, sampling or analyses. 2. Patients should have the ability and willingness to comply with the study and follow-up procedures. 3. Patients must have a solid tumor that is refractory to or intolerant of existing therapies known to provide clinical benefit for their clinical condition. 4. Age ≥ 18 5. Adequate organ function, determined by: * Absolute neutrophil count (ANC) ≥ 1.5 X 10\^9/L * Platelets ≥ 100 X 10\^9/L * Hemoglobin ≥ 9 g/dL * aPTT ≤1.5 x ULN * Total bilirubin ≤ 1.5 mg/dL * ALT and AST ≤ 2.5 x ULN if no liver involvement or ≤ 5 x ULN with liver involvement * Creatinine \<1.5 times ULN concurrent with creatinine clearance \>50 mL/min (measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is \>1.5 times ULN 6. Normotensive or well controlled blood pressure (BP) (\<140/90), with or without current antihypertensive treatment. If there is a diagnosis or history of hypertension, patient must have adequately controlled BP on a maximum of 2 antihypertensive medications, as demonstrated by 2 BP measurements taken in the clinical setting by a medical professional within 1 week prior to enrollment. It is strongly recommended that patients who are on antihypertensive medications be followed by a cardiologist or a primary care physician for management of BP while on the study. Patients on a hypertensive medication must be willing and able to check and record twice daily BP readings for a minimum of 3 weeks. 7. ECOG performance status of 0-1 8. Life expectancy ≥ 3 months 9. Ejection fraction (EF) \> 50% 10. Patients must have the ability to swallow and retain oral medication 11. Toxicities from prior therapy greater than CTCAE Grade 1 have resolved with the exception of alopecia. Patients with Grade ≤ 2 neuropathy are eligible. 12. Male patients with female partners of child-bearing potential must be willing to use two forms of acceptable contraception, including one barrier method, during their participation in this study and for 6 months after stopping study treatment with olaparib and/or AZD5153. Female partners of child-bearing potential of male patients must use at least one of the two forms of acceptable contraception. * Male patients must agree to refrain from donating sperm during their …
Enrollment public domain (ClinicalTrials.gov)
Enrollment: 49 participants (actual).